Developing Oversight Approaches to Nanobiotechnology: The Lessons of History

jlme

Published In

Journal of Law, Medicine & Ethics

Guest Editors

Gurumurthy Ramachandran

Jennifer Kuzma

Jordan Paradise

Issue

Winter, 2009

Issue Number

4

Volume

37

Symposium Articles

Introduction: The Challenge of Developing Oversight Approaches to Nanobiotechnology

Evaluating Oversight of Human Drugs and Medical Devices: A Case Study of the FDA and Implications for Nanobiotechnology

Commentary: Emerging Technologies Oversight: Research, Regulation and Commercialization

Commentary: Is It Possible to Determine the Extent to Which Informational Asymmetries and Prejudice Bias Responses?

Evaluating Oversight of Human Drugs and Medical Devices: A Case Study of the FDA and Implications for Nanobiotechnology

Commentary: Public Outreach by the FDA

Commentary: Evaluating Oversight of Human Drugs and Medical Devices

Review of the OSHA Framework for Oversight of Occupational Environments

Commentary: Oversight of Engineered Nanomaterials in the Workplace

Gene Therapy Oversight: Lesson for Nanobiotechnology

Commentary: Who's Afraid of the RAC? Lessons from the Oversight of Controversial Science

Developing U.S. Oversight Strategies for Nanobiotechnology: Learning from Past Oversight Experiences

Governance of Nanotechnology and Nanomaterials: Principles, Regulation, and Renegotiating the Social Contract

What Does the History of Technology Regulation Teach Us about Nano Oversight

Problem Formulation and Option Assessment (PFOA) Linking Governance and Environmental Risk Assessment for Technologies: A Methodology for Problem Analysis of Nanotechnologies and Genetically Engineered Organisms

Science, Ethics, and the "Problems" of Governing Nanotechnologies